Cardlytics Stock Forecast, Price & News

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CDLX shares have increased by 43.0% and is now trading at $65.52.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cardlytics.

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cardlytics.

Cardlytics Inc (NASDAQ:CDLX) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.36. The company earned $28.22 million during the quarter, compared to analyst estimates of $30.84 million. Cardlytics had a negative net margin of 18.86% and a negative return on equity of 26.42%. Cardlytics's revenue was down 42.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.12) earnings per share.
View Cardlytics' earnings history.

6 brokerages have issued twelve-month target prices for Cardlytics' stock. Their forecasts range from $26.00 to $80.00. On average, they expect Cardlytics' share price to reach $59.33 in the next twelve months. This suggests that the stock has a possible downside of 9.4%.
View analysts' price targets for Cardlytics.

Cardlytics saw a increase in short interest in June. As of June 30th, there was short interest totaling 3,890,000 shares, an increase of 23.5% from the June 15th total of 3,150,000 shares. Based on an average trading volume of 827,800 shares, the days-to-cover ratio is presently 4.7 days.
View Cardlytics' Short Interest.

Some companies that are related to Cardlytics include Legend Biotech (DADA), HUYA (HUYA), DouYu International (DOYU), Medallia (MDLA), Switch (SWCH), Rackspace Technology (RXT), SVMK (SVMK), Tripadvisor (TRIP), Pluralsight (PS), 21Vianet Group (VNET), Internet Initiative Japan (IIJIY), Sabre (SABR), Health Catalyst (HCAT), Model N (MODN) and Eventbrite (EB).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Square (SQ), Docusign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), Trade Desk (TTD), Walt Disney (DIS), Alibaba Group (BABA), QUALCOMM (QCOM) and Roku (ROKU).

(CDLX) raised $76 million in an initial public offering (IPO) on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.70%), Bank of New York Mellon Corp (1.76%), Frontier Capital Management Co. LLC (1.67%), Jennison Associates LLC (1.63%), Grantham Mayo Van Otterloo & Co. LLC (1.51%) and Victory Capital Management Inc. (1.16%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics.

CDLX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Grantham Mayo Van Otterloo & Co. LLC, Pier Capital LLC, RMB Capital Management LLC, Great West Life Assurance Co. Can, Two Sigma Advisers LP, Crosslink Capital Inc., and Teton Advisors Inc.. Company insiders that have sold Cardlytics company stock in the last year include Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, and Tony Weisman.
View insider buying and selling activity for Cardlytics.

CDLX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Great Lakes Advisors LLC, Nordea Investment Management AB, Clearfield Capital Management LP, Driehaus Capital Management LLC, Nuveen Asset Management LLC, First Trust Advisors LP, and Serengeti Asset Management LP. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDLX stock can currently be purchased for approximately $65.52.

Cardlytics has a market capitalization of $1.79 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]